Tisagenlecleucel (Kymriah) for Acute Lymphoblastic Leukemia – ModernMedicine
ModernMedicine |
Tisagenlecleucel (Kymriah) for Acute Lymphoblastic Leukemia
ModernMedicine Quote The FDA granted regular approval to tisagenlecleucel (Kymriah, Novartis) for the treatment of ALL that is refractory or in relapse in patients up to age 25.1 Tisagenlecleucel is a chimeric antigen receptor (CAR) T-cell immunotherapy agent. It is … |
